knowledge -WSS

knowledge

author：leisure time 2025-10-02 11:09:04 - browse：27

Judge's gavel — Legal experts unpacked the pharmaceutical industry's scattershot approach to challenging Medicare's new power to negotiate drug prices. Adobe

WASHINGTON — The pharmaceutical industry has been filing a lawsuit here, there, and pretty much everywhere.

Drugmakers lost a two-decade long lobbying fight in Congress last summer when Democrats gave Medicare more power to choose what it pays for prescription drugs. Now, they’re taking their battle to the courts.

Merck filed suit in the District of Columbia. Bristol Myers Squibb filed in New Jersey. The Chamber of Commerce filed in Ohio. PhRMA filed in Texas. And there’s no reason to believe the barrage of lawsuits will stop anytime soon.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The Supreme Court will review a ruling striking down a domestic violence federal gun ban
Next article： High breast density mammograms need follow

hotspot

WSS

Readout Newsletter: Parkinson's study, Gilead, CG Oncology

Immunocompromised patients offer clues on chronic Covid

Medicare bonuses could stop drug shortages under Senate plan

FDA endorses new sterilization method for medical devices

Pumping milk in bathrooms at health conferences is common

Christmas in the PICU brings some surprising joy

entertainment

knowledge

focus

Novavax promises a turnaround & Lilly roils the obesity market

In Spain, a hospital brews its own CAR

State Dept. review finds Biden bears some blame for Afghanistan failures

Virtual care provider acquires bankrupt Pear's prescription apps

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Immunocompromised patients offer clues on chronic Covid

Medicare proposal to cover medical devices draws a mixed reaction

Medicare drug price lawsuits could be good politics for Biden

FDA approval of Sarepta Duchenne genetic therapy gives me hope

SEC charges former device maker CEO with $41 million fraud

focus

Maisha Meds is a PBM, but don't call it that

Head of FDA's diagnostics center, who led through Covid, retires

FDA sets aggressive timeline for overhauling inspection procedures

SNAP should offer more nutrition education

Why health records don't always know when patients are dead

SNAP should offer more nutrition education

Wikipedia

hotspot

hotspot

entertainment